Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model

被引：14
|
作者：
Cortese, Brian D. [1 ]
Chang, Sam S. [2 ]
Talwar, Ruchika [2 ]
机构：
[1] Univ Penn Hlth Syst, Div Urol, Dept Surg, Philadelphia, PA USA
[2] Vanderbilt Univ, Dept Urol Surg, Nashville, TN USA
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷 / 02期
关键词：
Medicare Part D; health policy; drug prescriptions; drugs; generic; drug costs;
D O I：
10.1097/JU.0000000000003083
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：309 / 311
页数：3
相关论文
共 50 条
  • [1] Evaluation of Potential Urologic Prescription Drug Savings With Mark Cuban Cost Plus Drug Company
    Schloegel, Van
    Harris, Loyall
    Harris, Andrew
    Dropkin, Benjamin
    UROLOGY PRACTICE, 2024, 11 (02) : 276 - 282
  • [2] Improving affordability in dermatology: Increased cost savings in Mark Cuban cost plus drug company vs GoodRx
    Youn, G.
    Bae, G. H.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S56 - S56
  • [3] Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company
    Lalani, Hussain S.
    Kesselheim, Aaron S.
    Rome, Benjamin N.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (07) : 1053 - 1055
  • [4] Reducing men's health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings
    Khan, Adam
    Kari, Karim
    Oldham, Eli
    Duncan, Jacob
    Rashid, Matthew
    Vassar, Matt
    JOURNAL OF MENS HEALTH, 2024, 20 (12) : 57 - 64
  • [5] THE MARK CUBAN COST PLUS DRUG COMPANY EFFECT ON UROGYNECOLOGIC DRUGS
    Xu, Raymond
    El-Haraki, Amr S.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1144 - E1144
  • [6] Patient-Level Savings on Generic Drugs Through the Mark Cuban Cost Plus Drug Company
    Kouzy, Ramez
    El Alam, Molly B.
    Corrigan, Kelsey L.
    Lalani, Hussain S.
    Ludmir, Ethan B.
    JAMA HEALTH FORUM, 2024, 5 (06): : e241468
  • [7] Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug Program
    Gulati, Snigdha
    Gupta, Mohak
    Yan, Tingting
    Yelamanchili, Sneha
    Xu, Lucy Qinghua
    Bharani, Tina
    Naji, Ali
    Agarwal, Divyansh
    PHARMACOECONOMICS, 2024, 42 (11) : 1279 - 1286
  • [8] Potential Cost-Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications
    Buxo, Zachary
    Cramer, John D.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2025, 172 (02) : 693 - 696
  • [9] Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model
    Narendrula, Aparna
    Lang, Jacob
    Mossialos, Elias
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] AFFORDABLE HEPATOLOGY: EXPLORING THE POTENTIAL BENEFITS OF THE MARK CUBAN COST PLUS DRUG COMPANY MODEL FOR LIVER DISEASE TREATMENTS
    Moliya, Pratiksha
    Al-Obaidi, Hasan
    Saab, Omar
    Voruganti, Hima
    HEPATOLOGY, 2024, 80
12345